ARTICLE | Clinical News
ICT-107: Phase III started
June 13, 2016 7:00 AM UTC
ImmunoCellular began a double-blind, placebo-controlled, international Phase III trial to evaluate intradermal ICT-107 in combination with standard of care (SOC) temozolomide in about 414 patients fol...